Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31128508 | 1.00 | MAOA (0.53) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| Hydrochloric Acid SCHEMBL2883050 | 0.98 | MAOA (0.52) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| SCHEMBL11265174 | 0.96 | SIGMAR1 (0.57) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| SCHEMBL4323285 | 0.88 | CYP1A2 (0.53) | MAOAMAOBCYP2A6SIGMAR1CYP1A2 | |
| SCHEMBL29792666 | 0.88 | CYP1A2 (0.53) | MAOAMAOBCYP2A6SIGMAR1CYP1A2 | |
| SCHEMBL3599167 | 0.84 | MAOA (0.53) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| SCHEMBL29649256 | 0.84 | MAOA (0.53) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| Hydrochloric Acid SCHEMBL7258529 | 0.82 | MAOA (0.52) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| SCHEMBL8123725 | 0.80 | SIGMAR1 (0.57) | MAOAMAOBCYP2A6SIGMAR1PRKCI | |
| SCHEMBL15813775 | 0.76 | CDC7 (0.48) | SIGMAR1PKN1PKN2ROCK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104424-A1 | SARM1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-116444517-B | Carboxamide compound and application thereof in preparation of deubiquitinase USP28 inhibitor | 苏州大学 | 2024-06-21 | — | — | CN | disclosed |
| US-12006323-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-116444517-A | Carboxamide compound and application thereof in preparation of deubiquitinase USP28 inhibitor | 苏州大学 | 2023-07-18 | — | — | CN | disclosed |
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11034699-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2002076950-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1104407-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1036065-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6057329-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0946523-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999028300-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| WO-1998028281-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-5304554-A | Intercalators of DNA, inhibit replication of retroviruses | EMORY UNIVERSITY (US) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034699-B2 | Ethynyl derivatives | GRM4, GRM2, GRIA4 | MAOA 3240/4885MAOB 2785/4885CYP2A6 4326/4885 |
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | MAOA 825/4885MAOB 575/4885CYP2A6 2724/4885 |
| US-12006323-B2 | Ethynyl derivatives | GRM4, GRM2, GRIA4 | MAOA 3240/4885MAOB 2785/4885CYP2A6 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.